- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Profusa approves 1-for-25 reverse stock split; shares tumble | 1 | Seeking Alpha | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 02.07. | Profusa kündigt Aktienzusammenlegung im Verhältnis 1:25 mit Wirkung zum 7. Juli an | 1 | Investing.com Deutsch | ||
| 02.07. | Profusa announces 1-for-25 reverse stock split effective July 7 | 1 | Investing.com | ||
| 02.07. | Profusa, Inc.: Profusa Announces 1-for-25 Reverse Stock Split | 125 | GlobeNewswire (Europe) | BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology... ► Artikel lesen | |
| 24.06. | Profusa, Inc.: Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts | 184 | GlobeNewswire (Europe) | BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved... ► Artikel lesen | |
| 23.06. | Profusa Aktionäre genehmigen wichtige Vorstandsvorschläge inklusive Aktienzusammenlegung | 1 | Investing.com Deutsch | ||
| 23.06. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Profusa, Inc.: Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee Oxygen Platform | 213 | GlobeNewswire (Europe) | BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its... ► Artikel lesen | |
| 12.06. | Profusa submits response to European regulator for device approval | 2 | Investing.com | ||
| 10.06. | Profusa CEO urges shareholders to vote on Nasdaq listing proposals | 1 | Investing.com | ||
| 08.06. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Profusa moves to Nasdaq Capital Market amid compliance efforts | 1 | Investing.com | ||
| 15.05. | Profusa wechselt in den Nasdaq Capital Market, um Compliance-Anforderungen zu erfüllen | 5 | Investing.com Deutsch | ||
| 15.05. | Profusa, Inc.: Profusa Announces Listing Transfer to The Nasdaq Capital Market | 233 | GlobeNewswire (Europe) | BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling... ► Artikel lesen | |
| 08.05. | Profusa granted transfer to Nasdaq Capital Market, faces July compliance deadline | 1 | Seeking Alpha | ||
| 08.05. | Profusa, Inc.: Profusa Receives Favorable Nasdaq Listing Determination | 160 | GlobeNewswire (Europe) | BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the... ► Artikel lesen | |
| 08.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 8,058 | -2,61 % | Biotech Stocks At 52-Week Highs - CPIX, MRVI, ANGO, ACHC, TDOC | BENTONVILLE (dpa-AFX) - The following biotech stocks reached a 52-week high on July 15, 2026, driven by catalysts such as recent business developments or positive quarterly reports.Cumberland... ► Artikel lesen | |
| HIMS & HERS HEALTH | 28,780 | -2,24 % | Hims & Hers-Aktie +162%: Bereit für den nächsten Schub? | Die Hims & Hers-Aktie bleibt eine der spannendsten Turnaround-Storys im US-Healthcare-Sektor. Nach starker Erholung mitsamt Bruch des vorherigen Abwärtstrends konnten vom Februartief bis zum Junihoch... ► Artikel lesen | |
| PLUS THERAPEUTICS | 3,310 | -4,34 % | Plus Therapeutics Inc.: Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide CSF Assay Platform | HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration... ► Artikel lesen | |
| HEALWELL AI | 0,441 | +3,28 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| CO-DIAGNOSTICS | 2,440 | 0,00 % | Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer | SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented... ► Artikel lesen | |
| ORGANON | 11,790 | 0,00 % | Samsung Bioepis and Organon Broaden Biosimilar Access in Australia Through Expanded Commercialisation Agreement | ||
| VERU | 2,380 | 0,00 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,910 | +1,56 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 4,420 | -1,34 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| ELEKTA | 4,262 | -1,62 % | Elekta AB: Elekta presents financial targets and detailed outlook ahead of Capital Markets Day | STOCKHOLM - Elekta (EKTA-B.ST) today presents new mid-term financial targets and a more detailed outlook for fiscal year (FY) 2026/2027 ahead of its Capital Markets Day in Stockholm.
Elekta is planning... ► Artikel lesen | |
| IMUNON | 1,590 | -2,45 % | Celsion Bank wird Mitglied des Liechtensteinischen Bankenverbandes | Vaduz - Die Celsion Bank AG ist seit 1. Juli 2026 Vollmitglied des Liechtensteinischen Bankenverbandes (LBV). Die Celsion Bank bringt ein klares Profil mit Fokus auf digitale Vermögenswerte ein und... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,584 | +1,10 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor | SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering... ► Artikel lesen | |
| AXOGEN | 34,820 | +0,12 % | Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026 | ||
| PROCEPT BIOROBOTICS | 19,230 | 0,00 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| NIAGEN BIOSCIENCE | 2,900 | -2,68 % | Niagen Bioscience, Inc: Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) | Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience... ► Artikel lesen |
Das Unternehmen PROFUSA INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,76 % bei einem Aktienkurs von 1,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.